Lupin Gets EIR from US FDA for its Ankleshwar Manufacturing Facility

#Lupin #USFDA #Ankleshwar

Source: Lupin

“We are very happy to have received the EIR for our Ankleshwar facility from the US FDA. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.” - Nilesh Gupta, MD, Lupin

October 2022: Global pharma major Lupin Limited (Lupin) has recently announced that it has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility, located in Gujarat, India. The inspection of the facility was conducted from August 16-19, 2022.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “We are very happy to have received the EIR for our Ankleshwar facility from US FDA. We remain committed to enhancing compliance and quality standards across all our manufacturing sites.”